☆ 4.6 Article

Multi-targeted tyrosine kinase inhibitor reverses resistance to immunotherapy in hepatic sarcomatoid carcinoma

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

Matteo Santoni et al.

Summary: In the MOUSEION-03 study, a meta-analysis was conducted to determine the possibility of achieving complete remissions (CR) with immunotherapy or immuno-oncology combinations in cancer patients. The results showed that the use of immunotherapy can significantly increase the chance of achieving complete remission in cancer patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

添加到收藏夹

Review Oncology

The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study

Matteo Santoni et al.

Summary: The study aimed to evaluate the overall survival of male and female patients receiving immune checkpoint inhibitors. The findings showed that both male and female patients had improved overall survival with immunotherapy. However, the benefit was greater in male patients treated with single-agent immunotherapy.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Fan Zhang et al.

Summary: This study reports the long-term clinical outcomes of patients with NSCLC receiving PD-1 inhibitors as neoadjuvant therapy. The results show that patients with positive PD-L1 expression and high tumor mutation burden have favorable clinical outcomes.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study

Xiaofeng Chen et al.

Summary: This study investigated the safety and efficacy of immune checkpoint inhibitors plus antiangiogenic tyrosine kinase inhibitors as a first-line treatment for advanced hepatocellular carcinoma. The results showed promising clinical activities with manageable toxicity. Patients with lower LDH levels and a CONUT score <=2 had a significantly longer progression-free survival.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

A retrospective study on the clinical and pathological features of hepatic sarcomatoid carcinoma: Fourteen cases of a rare tumor

Shuoshuo Ma et al.

Summary: Hepatic sarcomatoid carcinoma is a rare and highly malignant liver tumor with atypical clinical symptoms. Imaging and pathological features are helpful for diagnosis, and radical surgery is the preferred treatment.

MEDICINE (2022)

添加到收藏夹

Article Oncology

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Tianqing Chu et al.

Summary: Although the evidence supporting the combination of immune checkpoint inhibitors and antiangiogenic tyrosine kinase inhibitors in treatment-naive patients with advanced NSCLC is insufficient, this report presented the efficacy and safety of sintilimab combined with anlotinib in a phase 1b trial. The study showed promising results with a high objective response rate and disease control rate, as well as manageable treatment-related adverse events.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Primary Liver Sarcomatoid Carcinoma: A Case Series and Literature Review

Wei Ji et al.

Summary: Primary liver sarcomatoid carcinoma (PLSC) is more prevalent in Asia with possibilities of misdiagnoses. Surgery remains an effective treatment, significantly prolonging overall survival for patients. Limited strategies are available for recurrent or advanced PLSC, with immunotherapy being a potential treatment option.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

添加到收藏夹

Article Oncology

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Shugeng Gao et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Anlotinib as a molecular targeted therapy for tumors

Yi Gao et al.

ONCOLOGY LETTERS (2020)

添加到收藏夹

Editorial Material Oncology

Adjuvant systemic treatment in hepatocellular carcinoma: tempted to do something, rather than nothing

Alessandro Rizzo et al.

FUTURE ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Clinical and imaging characteristics of primary hepatic sarcomatoid carcinoma and sarcoma: a comparative study

Dongli Shi et al.

BMC CANCER (2020)

添加到收藏夹

Review Oncology

Sintilimab: A Promising Anti-Tumor PD-1 Antibody

Lin Zhang et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Ming Yi et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Article Oncology

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Yihebali Chi et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Dal Fukurnura et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Guoshuang Shen et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Beatrice Seddon et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Yongkun Sun et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)

添加到收藏夹

Article Surgery

Carcinosarcoma of the liver: report of a case

Takatsugu Yamamoto et al.

SURGERY TODAY (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinicopathological Characteristics and Outcome of Primary Sarcomatoid Carcinoma and Carcinosarcoma of the Liver

Qi-Bo Wang et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2012)

添加到收藏夹

Article Oncology

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma - Retrospective analysis and identification of prognostic factors in 488 patients

Vasillos Karavasilis et al.

CANCER (2008)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Radiological and Clinical Features of Sarcomatoid Hepatocellular Carcinoma in 11 Cases

Hve Ryoung Koo et al.

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.